Drug Profile
Povidone iodine extended release - IVIEW Therapeutics
Alternative Names: In-situ gel povidone iodine ophthalmic drop - IVIEW Therapeutics; IVIEW 1201; IVIEW-1503; Povidone iodine slow releasing eye drop - IVIEW Therapeutics; Sustained release povidone iodine nasal spray - IVIEW Therapeutic; Sustained release povidone iodine ophthalmic drop - IVIEW TherapeuticsLatest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator IVIEW Therapeutics
- Class Antiseptics; Antivirals; Disinfectants; Eye disorder therapies; Oxidants; Pyrrolidinones; Skin disorder therapies
- Mechanism of Action Bacterial protein inhibitors; Bacterial protein modulators; Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Conjunctivitis
- Preclinical COVID 2019 infections
Most Recent Events
- 31 Dec 2023 IVIEW Therapeutics completes a phase II trial in Conjunctivitis (In adolescents, In adults, In the elderly) in USA, India, China (Ophthalmic) (NCT03749317)
- 12 Oct 2023 IVIEW Therapeutics completes a phase II trial for Conjunctivitis (In adolescents, In adults, In the elderly) in China (Opthalmic, Controlled release) (NCT05816070)
- 18 Apr 2023 IVIEW Therapeutics plans a phase II trial for Conjunctivitis (In adolescents, In adults, In the elderly) in June 2023 (Opthalmic, Controlled release) (NCT05816070)